Compare VOYA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | TWST |
|---|---|---|
| Founded | 1975 | 2013 |
| Country | United States | United States |
| Employees | N/A | 979 |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.4B |
| IPO Year | 2012 | 2018 |
| Metric | VOYA | TWST |
|---|---|---|
| Price | $102.32 | $113.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $109.00 | ★ $167.00 |
| AVG Volume (30 Days) | 908.9K | ★ 2.4M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 1.94 | ★ 63.89 |
| EPS | ★ 4.82 | N/A |
| Revenue | ★ $8,189,000,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $20.09 |
| Revenue Next Year | $4.80 | $18.30 |
| P/E Ratio | $21.20 | ★ N/A |
| Revenue Growth | 1.73 | ★ 20.32 |
| 52 Week Low | $64.50 | $24.41 |
| 52 Week High | $106.79 | $219.71 |
| Indicator | VOYA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 38.54 |
| Support Level | $93.15 | $79.90 |
| Resistance Level | $104.18 | $155.44 |
| Average True Range (ATR) | 3.00 | 16.82 |
| MACD | 0.42 | -3.05 |
| Stochastic Oscillator | 60.45 | 22.94 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.